Biotech catalyst calendar.
This calendar lists dated biotech events drawn from United States government records: regulatory actions the FDA has taken, advisory committee meetings noticed in the Federal Register, and trial completion dates sponsors have filed with ClinicalTrials.gov. It is rebuilt once a day, it is free, and every row links to the document it came from. Each row states how firm its date is, because most forward dates in biotech are estimates a company filed with a registry rather than commitments anyone has made.
Compiled . Methodology Recent changes Subscribe CSV JSON
Lane
Confidence
549 rows shown
Week of 3 August 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| FDA | Not named in the source | FDA approved Orzeyful (oveporexton) on 5 August 2026 to treat narcolepsy type 1. | Confirmed | FDA novel drug approvals table: 2026:Orzeyful | |
| FDA | Not named in the source | FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) on 6 August 2026. | Confirmed | FDA press announcement: FDA news release |
Week of 10 August 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Merck Sharp & Dohme | As of 5 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in hyperlipidemia, on 12 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07216482 | |
| Clinical | USWM CT | As of 25 February 2026, USWM CT estimated primary completion of a Phase 2 trial in Ovarian Cancer, on 12 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05601752 | |
| Clinical | Hinova Pharmaceuticals | As of 29 December 2025, Hinova Pharmaceuticals estimated primary completion of a Phase 2 trial in NAFLD (Non-alcoholic Fatty Liver Disease), on 13 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07308548 | |
| Clinical | Hoffmann-La Roche | As of 5 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Paroxysmal Hemoglobinuria, Nocturnal, on 13 August 2026. | Estimated | ClinicalTrials.gov registration: NCT03157635 | |
| Clinical | Zealand Pharma | As of 15 January 2026, Zealand Pharma estimated primary completion of a Phase 2 trial in overweight, on 13 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06926842 | |
| Clinical | pH-D Feminine Health | As of 3 August 2026, pH-D Feminine Health estimated primary completion of a Phase 3 trial in Vulvovaginal Candidiases, on 13 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07109869 | |
| Clinical | AstraZeneca | As of 27 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Erosive Esophagitis, on 14 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05267613 | |
| Clinical | Genzyme, a Sanofi | As of 22 June 2026, Genzyme, a Sanofi estimated primary completion of a Phase 3 trial in hemophilia, on 15 August 2026. | Estimated | ClinicalTrials.gov registration: NCT03974113 | |
| Clinical | PMV Pharmaceuticals | As of 10 August 2026, PMV Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 15 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04585750 | |
| Clinical | JenKem Technology Co. | As of 19 September 2024, JenKem Technology Co. estimated primary completion of a Phase 2 trial in Glioblastoma Multiforme (GBM), on 16 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06595186 |
Week of 17 August 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | BioArctic | As of 10 March 2026, BioArctic estimated primary completion of a Phase 2 trial in Parkinson Disease, on 17 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06671938 | |
| Clinical | Verona Pharma | As of 23 July 2026, Verona Pharma estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease, on 17 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07016412 | |
| Clinical | Janssen Sciences Ireland UC | As of 6 July 2026, Janssen Sciences Ireland UC estimated primary completion of a Phase 2 trial in Human Immunodeficiency Virus Type 1, on 18 August 2026. | Estimated | ClinicalTrials.gov registration: NCT02494986 | |
| Clinical | Merck Sharp & Dohme | As of 23 April 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Gastrointestinal Cancer, on 18 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06864169 | |
| Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. | As of 22 January 2026, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Triple Negative Breast Cancer, on 18 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06519370 | |
| Clinical | Amgen | As of 16 January 2026, Amgen estimated primary completion of a Phase 3 trial in Sjogren's Syndrome, on 19 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06104124 | |
| Clinical | ViiV Healthcare | As of 29 July 2026, ViiV Healthcare estimated primary completion of a Phase 3 trial in HIV Infections, on 19 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06694805 | |
| Clinical | AstraZeneca | As of 1 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Crohn's Disease, on 20 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06681324 | |
| Clinical | Boehringer Ingelheim | As of 7 August 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Chronic Kidney Disease, on 20 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06926660 | |
| Clinical | EMD Serono Research & Development Institute | As of 29 June 2026, EMD Serono Research & Development Institute estimated primary completion of a Phase 3 trial in Solid Tumors, on 21 August 2026. | Estimated | ClinicalTrials.gov registration: NCT03815643 | |
| Clinical | Longboard Pharmaceuticals | As of 10 August 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Dravet Syndrome, on 21 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06660394 | |
| Clinical | Merck Sharp & Dohme | As of 30 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Carcinoma, Renal Cell, on 21 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04626518 | |
| Clinical | Merck Sharp & Dohme | As of 30 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Carcinoma, Renal Cell, on 21 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04626479 | |
| Clinical | NodThera | As of 8 April 2026, NodThera estimated primary completion of a Phase 2 trial in obesity, on 21 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07220629 | |
| Clinical | Novo Nordisk | As of 5 December 2025, Novo Nordisk estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, on 21 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06797869 | |
| Clinical | Bazelet Nehushtan | As of 23 August 2024, Bazelet Nehushtan estimated primary completion of a Phase 2 trial in Attention Deficit Hyperactivity Disorder (ADHD), on 22 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06542445 | |
| Clinical | Hoffmann-La Roche | As of 11 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in obesity, on 22 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06965413 | |
| Clinical | Pfizer | As of 18 November 2024, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 23 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05262400 |
Week of 24 August 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Alexion Pharmaceuticals | As of 18 June 2026, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria, on 24 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05389449 | |
| Clinical | AstraZeneca | As of 14 October 2025, AstraZeneca estimated primary completion of a Phase 3 trial in ER-Positive HER2-Negative Breast Cancer, on 24 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04711252 | |
| Clinical | Regeneron Pharmaceuticals | As of 10 August 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Resectable Non-small Cell Lung Cancer, on 24 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06161441 | |
| Clinical | Suzhou HepaThera Biotech Co. | As of 19 September 2025, Suzhou HepaThera Biotech Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 24 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07183306 | |
| Clinical | BPGbio | As of 26 January 2026, BPGbio estimated primary completion of a Phase 2 trial in glioblastoma, on 25 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04752813 | |
| Clinical | Novartis Pharmaceuticals | As of 25 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 25 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05132075 | |
| Clinical | Sanofi | As of 7 July 2026, Sanofi estimated primary completion of a Phase 2 trial in Graves' Disease, on 25 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06984627 | |
| Clinical | Hoffmann-La Roche | As of 15 May 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 26 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06450639 | |
| Clinical | ParagonClinicals | As of 4 June 2026, ParagonClinicals estimated primary completion of a Phase 2 trial in Long COVID, on 26 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07627815 | |
| Clinical | Blue Earth Therapeutics | As of 14 May 2026, Blue Earth Therapeutics estimated primary completion of a Phase 2 trial in Prostate Cancer, on 27 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05413850 | |
| Clinical | 4Moving Biotech | As of 27 July 2026, 4Moving Biotech estimated primary completion of a Phase 2 trial in Knee Osteoarthritis, on 28 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07225829 | |
| Clinical | AstraZeneca | As of 14 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Carcinoma, on 28 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04995523 | |
| Clinical | Hoffmann-La Roche | As of 2 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Non-Small Cell Lung Cancer, on 28 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06624059 | |
| Clinical | Hoffmann-La Roche | As of 10 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Endometrial Cancer, on 28 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05634499 | |
| Clinical | Panbela Therapeutics | As of 6 November 2024, Panbela Therapeutics estimated primary completion of a Phase 3 trial in Pancreatic Cancer Metastatic, on 29 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05254171 | |
| Clinical | Beletalent (Zhuhai) Pharmaceutical Co. | As of 24 August 2025, Beletalent (Zhuhai) Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Proliferative Diabetic Retinopathy, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06817265 | |
| Clinical | Fujian Haixi Pharmaceuticals Co. | As of 28 November 2025, Fujian Haixi Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Solid Tumor, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06220318 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 17 November 2025, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06425341 | |
| Clinical | Haisco Pharmaceutical Group Co. | As of 8 April 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease (COPD), on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07108699 | |
| Clinical | Il-Yang Pharm. Co. | As of 30 May 2025, Il-Yang Pharm. Co. estimated primary completion of a Phase 3 trial in Peptic Ulcer, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06284876 | |
| Clinical | Innovent Biologics Technology | As of 8 January 2026, Innovent Biologics Technology estimated primary completion of a Phase 2 trial in Neovascular Age-related Macular Degeneration, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07275840 | |
| Clinical | Keymed Biosciences Co. | As of 2 October 2025, Keymed Biosciences Co. estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06495229 | |
| Clinical | NeuroPro Therapeutics | As of 29 May 2026, NeuroPro Therapeutics estimated primary completion of a Phase 2 trial in Epilepsy, Generalized, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06769659 | |
| Clinical | OncoC4 | As of 13 April 2026, OncoC4 estimated primary completion of a Phase 2 trial in Ovarian Cancer, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05446298 | |
| Clinical | Pfizer | As of 31 July 2026, Pfizer estimated primary completion of a Phase 3 trial in Multiple Myeloma, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06152575 | |
| Clinical | ReCode Therapeutics | As of 16 January 2026, ReCode Therapeutics estimated primary completion of a Phase 2 trial in Cystic Fibrosis, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06237335 | |
| Clinical | Satellos Bioscience | As of 23 April 2026, Satellos Bioscience estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy (DMD), on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06867107 | |
| Clinical | TCM Biotech International | As of 21 November 2024, TCM Biotech International estimated primary completion of a Phase 2 trial in Carcinoma, Hepatocellular, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT03812874 | |
| Clinical | TJ Biopharma Co. | As of 30 January 2026, TJ Biopharma Co. estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, on 30 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07005336 |
Week of 31 August 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AMAG Pharmaceuticals | As of 17 April 2026, AMAG Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Kidney Disease; Iron Deficiency Anemia, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT03619850 | |
| Clinical | Astellas Pharma Global Development | As of 14 July 2026, Astellas Pharma Global Development estimated primary completion of a Phase 2 trial in Pancreatic Cancer, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT03816163 | |
| Clinical | Bayer | As of 26 June 2026, Bayer estimated primary completion of a Phase 3 trial in Obstructive Hypertrophic Cardiomyopathy, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07023341 | |
| Clinical | Daewon Pharmaceutical Co. | As of 11 September 2025, Daewon Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Perennial Allergic Rhinitis Accompanied by Asthma, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07168473 | |
| Clinical | Daiichi Sankyo | As of 27 May 2026, Daiichi Sankyo estimated primary completion of a Phase 3 trial in Gastric Cancer, Adenocarcinoma, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04704934 | |
| Clinical | Galderma R&D | As of 30 October 2024, Galderma R&D estimated primary completion of a Phase 3 trial in Moderate-to-Severe Atopic Dermatitis, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT03989206 | |
| Clinical | Hansoh BioMedical R&D | As of 9 April 2026, Hansoh BioMedical R&D estimated primary completion of a Phase 3 trial in osteosarcoma, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06935409 | |
| Clinical | Hoffmann-La Roche | As of 15 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Primary IgA Nephropathy, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05797610 | |
| Clinical | Ipsen | As of 28 July 2026, Ipsen estimated primary completion of a Phase 2 trial in Moderate to Severe Upper Facial Lines, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04821089 | |
| Clinical | Kyowa Kirin Co. | As of 30 October 2025, Kyowa Kirin Co. estimated primary completion of a Phase 2 trial in Diabetic Macular Edema (DME), on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06116916 | |
| Clinical | Kyowa Kirin Co. | As of 30 October 2025, Kyowa Kirin Co. estimated primary completion of a Phase 2 trial in Neovascular Age-Related Macular Degeneration (nAMD), on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06116890 | |
| Clinical | Lumen Bioscience | As of 30 July 2026, Lumen Bioscience estimated primary completion of a Phase 3 trial in Clostridioides Difficile Infection, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05330182 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 9 March 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07202364 | |
| Clinical | Myrtelle | As of 14 November 2025, Myrtelle estimated primary completion of a Phase 2 trial in Canavan Disease, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT04833907 | |
| Clinical | Nantong Bencao Quadriga Medical Technology Co. | As of 13 April 2026, Nantong Bencao Quadriga Medical Technology Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06810804 | |
| Clinical | Pfizer | As of 2 June 2026, Pfizer estimated primary completion of a Phase 3 trial in Respiratory Syncytial Virus (RSV), on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07543380 | |
| Clinical | Santen Pharmaceutical Co. | As of 15 May 2026, Santen Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Open Angle Glaucoma, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06666855 | |
| Clinical | Shenyang Sunshine Pharmaceutical Co. | As of 18 December 2025, Shenyang Sunshine Pharmaceutical Co. estimated primary completion of a Phase 2 trial in First-line Advanced NSCLC Patients, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT07171606 | |
| Clinical | Sichuan Jishengtang Pharmaceutical Co. | As of 29 December 2025, Sichuan Jishengtang Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Alzheimer's Dementia, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06534723 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 19 March 2025, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in nSCLC, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT06844474 | |
| Clinical | Translational Sciences | As of 1 July 2026, Translational Sciences estimated primary completion of a Phase 2 trial in Pulmonary Embolism, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05408546 | |
| Clinical | UCB Biopharma SRL | As of 31 July 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05077904 | |
| Clinical | Verastem | As of 2 September 2025, Verastem estimated primary completion of a Phase 2 trial in KRAS Activating Mutation, on 31 August 2026. | Estimated | ClinicalTrials.gov registration: NCT05669482 | |
| Clinical | AbbVie | As of 31 July 2026, AbbVie estimated primary completion of a Phase 3 trial in Juvenile Psoriatic Arthritis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06100744 | |
| Clinical | Abscint NV/SA | As of 2 June 2026, Abscint NV/SA estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06369831 | |
| Clinical | Agitated Solutions | As of 6 July 2026, Agitated Solutions estimated primary completion of a Phase 3 trial in Right-To-Left Shunt, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06938347 | |
| Clinical | Alfasigma S.p.A. | As of 22 May 2026, Alfasigma S.p.A. estimated primary completion of a Phase 3 trial in Ulcerative Colitis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT02914535 | |
| Clinical | Alkermes | As of 3 June 2026, Alkermes estimated primary completion of a Phase 3 trial in schizophrenia, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05303064 | |
| Clinical | Amydis | As of 13 February 2026, Amydis estimated primary completion of a Phase 2 trial in Alzheimer Disease, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06514001 | |
| Clinical | Ardelyx | As of 4 June 2026, Ardelyx estimated primary completion of a Phase 3 trial in Irritable Bowel Syndrome With Constipation (IBS-C), on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05643534 | |
| Clinical | Arthrosi Therapeutics | As of 12 May 2026, Arthrosi Therapeutics estimated primary completion of a Phase 3 trial in gout, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06846515 | |
| Clinical | Atea Pharmaceuticals | As of 5 December 2025, Atea Pharmaceuticals estimated primary completion of a Phase 3 trial in HEPATITIS C VIRUS CHRONIC INFECTION, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06868264 | |
| Clinical | Beijing Continent Pharmaceutical Co | As of 19 November 2025, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 2 trial in Acute Liver Failure, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05689645 | |
| Clinical | Bio-Thera Solutions | As of 10 February 2025, Bio-Thera Solutions estimated primary completion of a Phase 3 trial in Cervical Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06123884 | |
| Clinical | Biohaven Therapeutics | As of 20 March 2026, Biohaven Therapeutics estimated primary completion of a Phase 2 trial in obesity, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07281495 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 2 July 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Esophageal Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07367516 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. | As of 30 July 2025, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gastroesophageal Adenocarcinoma, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06767800 | |
| Clinical | Clarity Pharmaceuticals | As of 14 May 2026, Clarity Pharmaceuticals estimated primary completion of a Phase 3 trial in Prostate Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06056830 | |
| Clinical | Clarity Pharmaceuticals | As of 6 May 2026, Clarity Pharmaceuticals estimated primary completion of a Phase 2 trial in Prostatic Neoplasms, Castration-Resistant, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT04868604 | |
| Clinical | Colgate Palmolive | As of 7 August 2026, Colgate Palmolive estimated primary completion of a Phase 3 trial in Dentinal Sensitivity, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07664592 | |
| Clinical | Cook MyoSite | As of 13 March 2026, Cook MyoSite estimated primary completion of a Phase 3 trial in Stress Urinary Incontinence, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT03104517 | |
| Clinical | Coordination Pharmaceuticals | As of 17 September 2025, Coordination Pharmaceuticals estimated primary completion of a Phase 2 trial in Head Neck Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05838729 | |
| Clinical | Corcept Therapeutics | As of 30 June 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in neoplasms, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07276373 | |
| Clinical | Corcept Therapeutics | As of 8 May 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Nonalcoholic Steatohepatitis (NASH), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06108219 | |
| Clinical | CuraSen Therapeutics | As of 30 July 2026, CuraSen Therapeutics estimated primary completion of a Phase 2 trial in Neurogenic Orthostatic Hypotension, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07089043 | |
| Clinical | Curium US | As of 4 June 2026, Curium US estimated primary completion of a Phase 3 trial in Prostate Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06235151 | |
| Clinical | Cytokinetics | As of 29 May 2026, Cytokinetics estimated primary completion of a Phase 2 trial in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06793371 | |
| Clinical | Design Therapeutics | As of 29 December 2025, Design Therapeutics estimated primary completion of a Phase 2 trial in Fuchs Endothelial Corneal Dystrophy, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07024693 | |
| Clinical | Disc Medicine | As of 3 August 2026, Disc Medicine estimated primary completion of a Phase 3 trial in Erythropoietic Protoporphyria (EPP), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06910358 | |
| Clinical | EIP Pharma | As of 6 July 2026, EIP Pharma estimated primary completion of a Phase 2 trial in Nonfluent Variant Primary Progressive Aphasia (nfvPPA), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07033481 | |
| Clinical | Edgewise Therapeutics | As of 31 July 2026, Edgewise Therapeutics estimated primary completion of a Phase 2 trial in Becker Muscular Dystrophy, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05291091 | |
| Clinical | Eli Lilly and | As of 8 May 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in overweight, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05536804 | |
| Clinical | Eli Lilly and | As of 22 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Perennial Allergic Rhinitis (PAR), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06339008 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 3 June 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in hyperlipidemia, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07100418 | |
| Clinical | Gasherbrum Bio | As of 27 April 2026, Gasherbrum Bio estimated primary completion of a Phase 2 trial in obese, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07400588 | |
| Clinical | Georgiamune | As of 11 July 2025, Georgiamune estimated primary completion of a Phase 2 trial in Advanced Solid Malignancies, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06028074 | |
| Clinical | Gilead Sciences | As of 18 June 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT02932150 | |
| Clinical | Gilead Sciences | As of 11 February 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05186974 | |
| Clinical | Glaukos | As of 27 February 2026, Glaukos estimated primary completion of a Phase 2 trial in Demodex Blepharitis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07400965 | |
| Clinical | GlaxoSmithKline | As of 24 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Head and Neck, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06062420 | |
| Clinical | Guangdong Hengrui Pharmaceutical Co. | As of 8 April 2026, Guangdong Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Moderate-to-severe Atopic Dermatitis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07211542 | |
| Clinical | Hexaell Biotech Co. | As of 25 February 2025, Hexaell Biotech Co. estimated primary completion of a Phase 2 trial in Acute on Chronic Hepatic Failure, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05989958 | |
| Clinical | Incyte | As of 1 April 2026, Incyte estimated primary completion of a Phase 3 trial in Diffuse Large B-cell Lymphoma, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04824092 | |
| Clinical | Initiator Pharma | As of 5 February 2026, Initiator Pharma estimated primary completion of a Phase 2 trial in vulvodynia, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07391241 | |
| Clinical | Jiangsu BioJeTay Biotechnology Co. | As of 23 April 2026, Jiangsu BioJeTay Biotechnology Co. estimated primary completion of a Phase 3 trial in hemophilia, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06922045 | |
| Clinical | Karyopharm Therapeutics | As of 2 July 2026, Karyopharm Therapeutics estimated primary completion of a Phase 2 trial in myelofibrosis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT04562870 | |
| Clinical | Lubris Bio Pty | As of 20 January 2026, Lubris Bio Pty estimated primary completion of a Phase 2 trial in Ocular Graft Versus Host Disease, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07118254 | |
| Clinical | Mabwell (Shanghai) Bioscience Co. | As of 21 November 2024, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05990452 | |
| Clinical | Mabwell (Shanghai) Bioscience Co. | As of 13 April 2025, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 3 trial in Advanced Urothelial Carcinoma, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06196736 | |
| Clinical | Maze Therapeutics | As of 27 July 2026, Maze Therapeutics estimated primary completion of a Phase 2 trial in Proteinuric Kidney Disease, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06830629 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 12 September 2025, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07169994 | |
| Clinical | Nacuity Pharmaceuticals | As of 13 April 2026, Nacuity Pharmaceuticals estimated primary completion of a Phase 2 trial in cataract, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05026632 | |
| Clinical | NewAmsterdam Pharma | As of 20 October 2025, NewAmsterdam Pharma estimated primary completion of a Phase 2 trial in Antioxidant Absorption, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06982508 | |
| Clinical | Novo Nordisk | As of 11 March 2026, Novo Nordisk estimated primary completion of a Phase 2 trial in Chronic Kidney Disease, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06717698 | |
| Clinical | ORIC Pharmaceuticals | As of 5 August 2025, ORIC Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumors, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05315700 | |
| Clinical | Octapharma | As of 6 August 2026, Octapharma estimated primary completion of a Phase 3 trial in Primary Immune Deficiency, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT04640142 | |
| Clinical | Pfizer | As of 10 February 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05548127 | |
| Clinical | Pharmazz | As of 24 June 2026, Pharmazz estimated primary completion of a Phase 3 trial in Acute Ischemic Stroke, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05691244 | |
| Clinical | Processa Pharmaceuticals | As of 19 June 2025, Processa Pharmaceuticals estimated primary completion of a Phase 2 trial in Breast Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06568692 | |
| Clinical | Qilu Pharmaceutical Co. | As of 6 August 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Chemotherapy-induced Peripheral Neuropathy (CIPN), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06994507 | |
| Clinical | Qlaris Bio | As of 6 July 2026, Qlaris Bio estimated primary completion of a Phase 2 trial in Non-proliferative Diabetic Retinopathy (NPDR), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07354477 | |
| Clinical | R-Pharm International | As of 8 April 2026, R-Pharm International estimated primary completion of a Phase 2 trial in Juvenile Idiopathic Arthritis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07517575 | |
| Clinical | REGENXBIO | As of 21 July 2026, REGENXBIO estimated primary completion of a Phase 3 trial in Duchenne Muscular Dystrophy, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05693142 | |
| Clinical | Repurposed Therapeutics | As of 16 May 2024, Repurposed Therapeutics estimated primary completion of a Phase 2 trial in Motion Sickness, Space, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05852730 | |
| Clinical | Ribocure Pharmaceuticals | As of 3 February 2026, Ribocure Pharmaceuticals estimated primary completion of a Phase 2 trial in Chronic Hepatitis D, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06649266 | |
| Clinical | ScandiBio Therapeutics | As of 6 February 2026, ScandiBio Therapeutics estimated primary completion of a Phase 3 trial in Alzheimer Disease, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07062198 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 20 August 2025, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 3 trial in Obstructive Hypertrophic Cardiomyopathy, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07021976 | |
| Clinical | Shanghai HyaMab Biotech Co. | As of 15 December 2023, Shanghai HyaMab Biotech Co. estimated primary completion of a Phase 2 trial in Locally Advanced/Metastatic Solid Tumors, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05801237 | |
| Clinical | Sichuan Purity Pharmaceutical Technology Co. | As of 29 January 2026, Sichuan Purity Pharmaceutical Technology Co. estimated primary completion of a Phase 2 trial in migraine, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07304518 | |
| Clinical | Silence Therapeutics | As of 19 December 2025, Silence Therapeutics estimated primary completion of a Phase 2 trial in Polycythemia Vera, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05499013 | |
| Clinical | Sinovac Life Sciences Co. | As of 24 December 2025, Sinovac Life Sciences Co. estimated primary completion of a Phase 2 trial in Pneumococcal Infectious Disease, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07300644 | |
| Clinical | Supernus Pharmaceuticals | As of 15 July 2026, Supernus Pharmaceuticals estimated primary completion of a Phase 3 trial in Attention-Deficit/Hyperactivity Disorder, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT02736656 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 4 May 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 3 trial in Advanced Hepatocellular Carcinoma, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06618664 | |
| Clinical | Suzhou Zelgen Biopharmaceuticals Co. | As of 16 December 2024, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06558227 | |
| Clinical | Suzhou Zelgen Biopharmaceuticals Co. | As of 5 January 2026, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Small Cell Lung Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05978284 | |
| Clinical | Syndax Pharmaceuticals | As of 27 March 2026, Syndax Pharmaceuticals estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06132256 | |
| Clinical | TYK Medicines | As of 29 April 2025, TYK Medicines estimated primary completion of a Phase 2 trial in HR-positive, HER2-negative Advanced Breast Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06950086 | |
| Clinical | Tango Therapeutics | As of 6 July 2026, Tango Therapeutics estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT05887492 | |
| Clinical | Tarian Pharma | As of 10 February 2025, Tarian Pharma estimated primary completion of a Phase 2 trial in EGFR Inhibitor-associated Rash, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06818058 | |
| Clinical | Tiziana Life Sciences | As of 2 July 2026, Tiziana Life Sciences estimated primary completion of a Phase 2 trial in Secondary Progressive Multiple Sclerosis, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06292923 | |
| Clinical | Tourmaline Bio, Inc., a Novartis | As of 23 April 2026, Tourmaline Bio, Inc., a Novartis estimated primary completion of a Phase 2 trial in Thyroid Eye Disease, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06088979 | |
| Clinical | UCB BIOSCIENCES | As of 7 August 2026, UCB BIOSCIENCES estimated primary completion of a Phase 3 trial in Dravet Syndrome, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06118255 | |
| Clinical | Vanda Pharmaceuticals | As of 17 September 2025, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in Dry Eye, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07179055 | |
| Clinical | Vanda Pharmaceuticals | As of 4 February 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in Onychomycosis of Toenail, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07065773 | |
| Clinical | Vanda Pharmaceuticals | As of 27 July 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Sleep Wake Disorders, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT04652882 | |
| Clinical | Vera Therapeutics | As of 13 April 2026, Vera Therapeutics estimated primary completion of a Phase 2 trial in IgA Nephropathy (IgAN), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT07020923 | |
| Clinical | Vigonvita Life Sciences | As of 20 May 2026, Vigonvita Life Sciences estimated primary completion of a Phase 2 trial in mDD, on 1 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06828887 | |
| Clinical | Wave Life Sciences USA | As of 14 April 2026, Wave Life Sciences USA estimated primary completion of a Phase 2 trial in Alpha-1 Antitrypsin Deficiency, in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06405633 | |
| Clinical | argenx | As of 20 May 2026, argenx estimated primary completion of a Phase 3 trial in Multifocal Motor Neuropathy (MMN), in September 2026. | Estimated | ClinicalTrials.gov registration: NCT06742190 | |
| Clinical | Boehringer Ingelheim | As of 23 July 2026, Boehringer Ingelheim estimated primary completion of a Phase 3 trial in Lung Cancer, Non-squamous, Non-small Cell, on 2 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06151574 | |
| Clinical | Pfizer | As of 19 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Pulmonary Arterial Hypertension, on 2 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06137742 | |
| Clinical | Sanofi | As of 6 August 2026, Sanofi estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus, on 3 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05039840 | |
| Clinical | Clear Scientific | As of 7 July 2026, Clear Scientific estimated primary completion of a Phase 2 trial in Methamphetamine Intoxication, on 4 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06721494 | |
| Clinical | Bristol-Myers Squibb | As of 2 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 5 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06730750 | |
| Clinical | H. Lundbeck | As of 14 July 2026, H. Lundbeck estimated primary completion of a Phase 3 trial in Chronic Migraine in Children, on 5 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04965675 | |
| Clinical | Merck Sharp & Dohme | As of 12 June 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Arthritis, Rheumatoid, on 5 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07176390 | |
| Clinical | ALK-Abelló | As of 20 July 2026, ALK-Abelló estimated primary completion of a Phase 3 trial in Allergic Rhinoconjunctivitis, on 6 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07060885 | |
| Clinical | CastleVax | As of 22 July 2026, CastleVax estimated primary completion of a Phase 2 trial in cOVID-19, on 6 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07215520 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 14 April 2026, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia, on 6 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07473960 |
Week of 7 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | ViiV Healthcare | As of 18 November 2025, ViiV Healthcare estimated primary completion of a Phase 2 trial in HIV Infections, on 9 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06741397 | |
| Clinical | Galaxy Therapeutics | As of 16 January 2026, Galaxy Therapeutics estimated primary completion of a Phase 3 trial in Intracranial Aneurysm, on 10 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05831202 | |
| Clinical | GlaxoSmithKline | As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 10 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06855160 | |
| Clinical | Shanghai Vitalgen BioPharma Co. | As of 31 March 2026, Shanghai Vitalgen BioPharma Co. estimated primary completion of a Phase 2 trial in Parkinson's Disease, on 10 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06480461 | |
| Clinical | NS Pharma | As of 6 March 2026, NS Pharma estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 11 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05996003 | |
| Clinical | Priovant Therapeutics | As of 12 January 2026, Priovant Therapeutics estimated primary completion of a Phase 3 trial in Uveitis, Posterior, on 11 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06431373 | |
| Clinical | Grit Biotechnology | As of 27 April 2026, Grit Biotechnology estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 13 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06144671 |
Week of 14 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bayer | As of 6 July 2026, Bayer estimated primary completion of a Phase 2 trial in Hemophilia A, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT03588299 | |
| Clinical | H. Lundbeck | As of 12 June 2026, H. Lundbeck estimated primary completion of a Phase 2 trial in Cushing's Disease, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06471829 | |
| Clinical | Merck Sharp & Dohme | As of 24 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Endometrial Neoplasms, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04634877 | |
| Clinical | Pfizer | As of 1 June 2026, Pfizer estimated primary completion of a Phase 2 trial in Obesity and Obesity-related Medical Conditions, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06924320 | |
| Clinical | Teva Branded Pharmaceutical Products R&D | As of 27 July 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 2 trial in Celiac Disease, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06807463 | |
| Clinical | Thirty Respiratory | As of 12 January 2026, Thirty Respiratory estimated primary completion of a Phase 2 trial in Pulmonary Tuberculoses, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07073638 | |
| Clinical | Wuhan YZY Biopharma Co. | As of 8 July 2026, Wuhan YZY Biopharma Co. estimated primary completion of a Phase 2 trial in Malignant Pleural Effusions, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05543330 | |
| Clinical | Hoffmann-La Roche | As of 6 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Multiple Sclerosis, on 17 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07074886 | |
| Clinical | Vertex Pharmaceuticals Incorporated | As of 23 March 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Type 1 Diabetes, on 17 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06832410 | |
| Clinical | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | As of 8 September 2025, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in sCLC, on 18 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07145333 | |
| Clinical | Takeda | As of 6 July 2026, Takeda estimated primary completion of a Phase 2 trial in Crohn's Disease, on 18 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06233461 | |
| Clinical | Teva Branded Pharmaceutical Products R&D | As of 25 June 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 19 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06664619 | |
| Clinical | Bharat Biotech International | As of 29 April 2026, Bharat Biotech International estimated primary completion of a Phase 3 trial in Active Immunisation for Chikungunya Virus Infection, on 20 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07555392 | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 12 December 2025, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Obesity & Overweight, on 20 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07279194 |
Week of 21 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Cardiol Therapeutics | As of 23 July 2026, Cardiol Therapeutics estimated primary completion of a Phase 3 trial in Recurrent Pericarditis, on 21 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06708299 | |
| Clinical | BeOne Medicines | As of 2 January 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Waldenstrom Macroglobulinemia, on 22 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05952037 | |
| Clinical | ImmVira Pharma Co. | As of 8 October 2025, ImmVira Pharma Co. estimated primary completion of a Phase 2 trial in Solid Tumor, on 22 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04370587 | |
| Clinical | Merck Sharp & Dohme | As of 22 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 22 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05468697 | |
| Clinical | ModernaTX | As of 3 April 2026, ModernaTX estimated primary completion of a Phase 2 trial in Norovirus Acute Gastroenteritis, on 22 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05992935 | |
| Clinical | Pfizer | As of 1 October 2025, Pfizer estimated primary completion of a Phase 2 trial in liposarcoma, on 23 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04557449 | |
| Clinical | Sinocelltech | As of 4 September 2025, Sinocelltech estimated primary completion of a Phase 2 trial in nAMD, on 23 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06672536 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 11 July 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in obesity, on 24 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06862908 | |
| Clinical | Novartis Pharmaceuticals | As of 24 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus, on 24 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05798117 | |
| Clinical | Biogen | As of 29 January 2026, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 27 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04961567 |
Week of 28 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AstraZeneca | As of 17 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Gastric Cancer, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07143604 | |
| Clinical | Attralus | As of 6 May 2026, Attralus estimated primary completion of a Phase 2 trial in Amyloidosis; Systemic, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05951049 | |
| Clinical | Incyte | As of 24 February 2026, Incyte estimated primary completion of a Phase 2 trial in Cutaneous Squamous Cell Carcinoma, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05888844 | |
| Clinical | MoonLake Immunotherapeutics | As of 6 May 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06768671 | |
| Clinical | Ocugen | As of 31 July 2026, Ocugen estimated primary completion of a Phase 3 trial in Stargardt Disease, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05956626 | |
| Clinical | GlaxoSmithKline | As of 8 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Eosinophilic Granulomatosis With Polyangiitis, on 29 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05263934 | |
| Clinical | Sanofi | As of 20 May 2026, Sanofi estimated primary completion of a Phase 2 trial in asthma, on 29 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06033833 | |
| Clinical | Accro Bioscience (Suzhou) | As of 24 July 2025, Accro Bioscience (Suzhou) estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07083193 | |
| Clinical | Allist Pharmaceuticals | As of 4 April 2025, Allist Pharmaceuticals estimated primary completion of a Phase 3 trial in Advanced Non-squamous Non-small-cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06416410 | |
| Clinical | Arrowhead Pharmaceuticals | As of 13 July 2026, Arrowhead Pharmaceuticals estimated primary completion of a Phase 2 trial in Hyperlipidemia; Mixed, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07223658 | |
| Clinical | AstraZeneca | As of 4 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in dyslipidaemia, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07218900 | |
| Clinical | AstraZeneca | As of 26 June 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Hepatocellular Carcinoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05557838 | |
| Clinical | AstraZeneca | As of 18 June 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05221840 | |
| Clinical | AstraZeneca | As of 14 May 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Metastatic Non-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06417814 | |
| Clinical | Beijing Continent Pharmaceutical Co | As of 24 November 2025, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in pneumoconiosis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05288179 | |
| Clinical | Beijing Pearl Biotechnology Limited Liability | As of 29 June 2025, Beijing Pearl Biotechnology Limited Liability estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05989542 | |
| Clinical | BioInvent International | As of 24 April 2025, BioInvent International estimated primary completion of a Phase 2 trial in Indolent B-Cell Non-Hodgkin Lymphoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT03571568 | |
| Clinical | Biogen | As of 10 February 2026, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04895241 | |
| Clinical | Bristol-Myers Squibb | As of 11 June 2025, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05888831 | |
| Clinical | CSPC Ouyi Pharmaceutical Co. | As of 6 May 2025, CSPC Ouyi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Major Depressive Disorder (MDD), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06958692 | |
| Clinical | Cantex Pharmaceuticals | As of 31 March 2026, Cantex Pharmaceuticals estimated primary completion of a Phase 2 trial in glioblastoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05986851 | |
| Clinical | Chongqing Claruvis Pharmaceutical Co. | As of 22 January 2026, Chongqing Claruvis Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Upper Limb Spasticity, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06783114 | |
| Clinical | Daiichi Sankyo | As of 6 February 2026, Daiichi Sankyo estimated primary completion of a Phase 2 trial in Extensive Stage-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06362252 | |
| Clinical | EIP Pharma | As of 8 July 2026, EIP Pharma estimated primary completion of a Phase 2 trial in Moderate to Severe Acute Ischaemic Stroke, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06987643 | |
| Clinical | EMD Serono Research & Development Institute | As of 28 May 2026, EMD Serono Research & Development Institute estimated primary completion of a Phase 2 trial in Non-Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05882734 | |
| Clinical | EveryONE Medicines | As of 17 March 2026, EveryONE Medicines estimated primary completion of a Phase 2 trial in Pediatric SDLT CNS Disorders, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07410143 | |
| Clinical | EyeBiotech | As of 26 June 2026, EyeBiotech estimated primary completion of a Phase 3 trial in Diabetic Macular Edema (DME), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06571045 | |
| Clinical | GlaxoSmithKline | As of 14 November 2025, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06079190 | |
| Clinical | GlaxoSmithKline | As of 22 June 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in cholestasis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04167358 | |
| Clinical | GlaxoSmithKline | As of 29 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Respiratory Syncytial Virus Infections, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06534892 | |
| Clinical | GlaxoSmithKline | As of 19 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Salmonella Infections, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06213506 | |
| Clinical | Glycomine | As of 27 February 2026, Glycomine estimated primary completion of a Phase 3 trial in Phosphomannomutase 2 Deficiency, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06892288 | |
| Clinical | Graegis Pharmaceuticals | As of 25 September 2025, Graegis Pharmaceuticals estimated primary completion of a Phase 2 trial in Radiodermatitis; Acute, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07192588 | |
| Clinical | H. Lundbeck | As of 9 March 2026, H. Lundbeck estimated primary completion of a Phase 2 trial in Congenital Adrenal Hyperplasia, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05669950 | |
| Clinical | Hansoh BioMedical R&D | As of 16 October 2024, Hansoh BioMedical R&D estimated primary completion of a Phase 3 trial in Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06498479 | |
| Clinical | Hoffmann-La Roche | As of 17 February 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in lymphoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04980222 | |
| Clinical | ImmunityBio | As of 31 March 2026, ImmunityBio estimated primary completion of a Phase 2 trial in Non-muscle Invasive Bladder Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT02138734 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 26 June 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05116462 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 15 December 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in obesity, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07000955 | |
| Clinical | Innovent Biopharmaceutical Technology (Hangzhou) Co. | As of 22 December 2025, Innovent Biopharmaceutical Technology (Hangzhou) Co. estimated primary completion of a Phase 3 trial in psoriasis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07265284 | |
| Clinical | J Ints Bio | As of 16 May 2025, J Ints Bio estimated primary completion of a Phase 2 trial in EGFR Mutant Advanced Non-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05394831 | |
| Clinical | Joincare Pharmaceutical Group Industry Co. | As of 20 January 2026, Joincare Pharmaceutical Group Industry Co. estimated primary completion of a Phase 2 trial in COPD (Chronic Obstructive Pulmonary Disease), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07351734 | |
| Clinical | Kahr Bio Australia Pty | As of 8 June 2026, Kahr Bio Australia Pty estimated primary completion of a Phase 2 trial in Colorectal Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07235293 | |
| Clinical | Mirati Therapeutics | As of 23 June 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced NSCLC, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05609578 | |
| Clinical | Novartis Pharmaceuticals | As of 15 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS G12C Mutant Solid Tumors, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05358249 | |
| Clinical | OM Pharma SA | As of 23 February 2026, OM Pharma SA estimated primary completion of a Phase 2 trial in Recurrent Wheezing, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05857930 | |
| Clinical | Shanghai JMT-Bio | As of 16 December 2024, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial in Locally Advanced or Metastatic Non-squamous NSCLC, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06735391 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 6 August 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Advanced Melanoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06214156 | |
| Clinical | Stamford Pharmaceuticals | As of 20 September 2024, Stamford Pharmaceuticals estimated primary completion of a Phase 2 trial in Basal Cell Carcinoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06344052 | |
| Clinical | SyneuRx International (Taiwan) | As of 13 September 2021, SyneuRx International (Taiwan) estimated primary completion of a Phase 3 trial in Refractory Schizophrenia, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT03094429 | |
| Clinical | Takeda | As of 6 May 2026, Takeda estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06254950 | |
| Clinical | Turning Point Therapeutics | As of 19 November 2025, Turning Point Therapeutics estimated primary completion of a Phase 2 trial in Locally Advanced Solid Tumors, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04094610 | |
| Clinical | Umecrine Cognition | As of 26 June 2026, Umecrine Cognition estimated primary completion of a Phase 2 trial in Primary Biliary Cholangitis (PBC), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07304843 | |
| Clinical | UniQure Biopharma B.V. | As of 22 October 2025, UniQure Biopharma B.V. estimated primary completion of a Phase 2 trial in Amyotrophic Lateral Sclerosis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06100276 | |
| Clinical | Uniquity One | As of 11 August 2026, Uniquity One estimated primary completion of a Phase 2 trial in cOPD, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06496620 | |
| Clinical | argenx | As of 4 June 2026, argenx estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06392386 | |
| Clinical | AbbVie | As of 3 August 2026, AbbVie estimated primary completion of a Phase 3 trial in aMD, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05407636 | |
| Clinical | Actinogen Medical | As of 21 July 2026, Actinogen Medical estimated primary completion of a Phase 3 trial in Dementia Moderate, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06125951 | |
| Clinical | Acumen Pharmaceuticals | As of 27 October 2025, Acumen Pharmaceuticals estimated primary completion of a Phase 2 trial in Alzheimer Disease, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06335173 | |
| Clinical | Akeso | As of 21 January 2026, Akeso estimated primary completion of a Phase 3 trial in Biliary Tract Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06591520 | |
| Clinical | Aldena Therapeutics | As of 4 March 2026, Aldena Therapeutics estimated primary completion of a Phase 2 trial in Alopecia Areata (AA), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06826196 | |
| Clinical | Aramis Biotechnologies | As of 4 August 2026, Aramis Biotechnologies estimated primary completion of a Phase 2 trial in influenza, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07291635 | |
| Clinical | Beijing Dongfang Biotech Co. | As of 17 September 2025, Beijing Dongfang Biotech Co. estimated primary completion of a Phase 3 trial in Type2 Diabetes Mellitus, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06257966 | |
| Clinical | Beijing InnoCare Pharma Tech Co. | As of 31 December 2025, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 2 trial in Plaque Psoriasis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07251998 | |
| Clinical | BioAegis Therapeutics | As of 15 June 2026, BioAegis Therapeutics estimated primary completion of a Phase 2 trial in Acute Respiratory Distress Syndrome, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05947955 | |
| Clinical | Biohaven Therapeutics | As of 1 July 2026, Biohaven Therapeutics estimated primary completion of a Phase 3 trial in Focal Epilepsy, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06309966 | |
| Clinical | CanSino Biologics | As of 6 August 2026, CanSino Biologics estimated primary completion of a Phase 2 trial in poliomyelitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06577298 | |
| Clinical | Celldex Therapeutics | As of 25 March 2026, Celldex Therapeutics estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06445023 | |
| Clinical | Celldex Therapeutics | As of 25 March 2026, Celldex Therapeutics estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06455202 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 26 April 2024, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Non Small Cell Lung Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06300177 | |
| Clinical | Citryll BV | As of 30 January 2026, Citryll BV estimated primary completion of a Phase 2 trial in rA, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07147959 | |
| Clinical | Cocrystal Pharma | As of 17 February 2026, Cocrystal Pharma estimated primary completion of a Phase 2 trial in norovirus, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07198139 | |
| Clinical | Corcept Therapeutics | As of 16 June 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Amyotrophic Lateral Sclerosis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05407324 | |
| Clinical | Crinetics Pharmaceuticals | As of 4 June 2026, Crinetics Pharmaceuticals estimated primary completion of a Phase 2 trial in Cushing Syndrome, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05804669 | |
| Clinical | Debiopharm International SA | As of 27 July 2026, Debiopharm International SA estimated primary completion of a Phase 3 trial in Central Precocious Puberty, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06129539 | |
| Clinical | Disc Medicine | As of 3 August 2026, Disc Medicine estimated primary completion of a Phase 2 trial in Inflammatory Bowel Disease (IBD), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07368972 | |
| Clinical | Eli Lilly and | As of 11 August 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Systemic Juvenile Idiopathic Arthritis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04088396 | |
| Clinical | Eli Lilly and | As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 2 Diabetes, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06297603 | |
| Clinical | Endeavor Biomedicines | As of 24 February 2026, Endeavor Biomedicines estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06422884 | |
| Clinical | EyePoint Pharmaceuticals | As of 4 August 2026, EyePoint Pharmaceuticals estimated primary completion of a Phase 3 trial in Wet Age Related Macular Degeneration, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06683742 | |
| Clinical | Fujian Akeylink Biotechnology Co. | As of 17 July 2026, Fujian Akeylink Biotechnology Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07709520 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 29 June 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07233070 | |
| Clinical | GEn1E Lifesciences | As of 23 June 2026, GEn1E Lifesciences estimated primary completion of a Phase 2 trial in Respiratory Distress Syndrome, Acute, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05795465 | |
| Clinical | GIE Medical | As of 25 June 2025, GIE Medical estimated primary completion of a Phase 3 trial in Esophageal Stricture, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05561114 | |
| Clinical | Gilead Sciences | As of 17 November 2025, Gilead Sciences estimated primary completion of a Phase 2 trial in Solid Tumor, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05119907 | |
| Clinical | Gilgamesh Pharmaceuticals | As of 9 February 2026, Gilgamesh Pharmaceuticals estimated primary completion of a Phase 2 trial in Major Depressive Disorder, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06236880 | |
| Clinical | Housey Healthcare ULC | As of 23 April 2026, Housey Healthcare ULC estimated primary completion of a Phase 2 trial in Type 2 Diabetes, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07546929 | |
| Clinical | ImmunityBio | As of 11 May 2026, ImmunityBio estimated primary completion of a Phase 2 trial in Long COVID, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07108036 | |
| Clinical | Immunocore | As of 6 March 2026, Immunocore estimated primary completion of a Phase 2 trial in Select Advanced Solid Tumors, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04262466 | |
| Clinical | Immunovant Sciences | As of 10 July 2026, Immunovant Sciences estimated primary completion of a Phase 2 trial in Subacute Cutaneous Lupus Erythematosus, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06980805 | |
| Clinical | Industrial Farmacéutica Cantabria | As of 12 May 2026, Industrial Farmacéutica Cantabria estimated primary completion of a Phase 3 trial in Androgenetic Alopecia, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05888922 | |
| Clinical | Ingenia Therapeutics | As of 18 May 2026, Ingenia Therapeutics estimated primary completion of a Phase 2 trial in Healthy Volunteers, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07231679 | |
| Clinical | Inhatarget Therapeutics | As of 26 March 2025, Inhatarget Therapeutics estimated primary completion of a Phase 2 trial in NSCLC (advanced Non-small Cell Lung Cancer), on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06896890 | |
| Clinical | Inmunotek S.L. | As of 13 May 2025, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis, Allergic, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04898283 | |
| Clinical | Kynexis B.V. | As of 23 June 2026, Kynexis B.V. estimated primary completion of a Phase 2 trial in Cognitive Impairment Associated With Schizophrenia (CIAS), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07191483 | |
| Clinical | Lallemand Health Solutions | As of 18 June 2026, Lallemand Health Solutions estimated primary completion of a Phase 2 trial in Focus is on Healthy Subjects, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07246161 | |
| Clinical | Laminar Pharmaceuticals | As of 20 November 2025, Laminar Pharmaceuticals estimated primary completion of a Phase 2 trial in High-grade Glioma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04299191 | |
| Clinical | Loxo Oncology | As of 29 January 2026, Loxo Oncology estimated primary completion of a Phase 3 trial in Chronic Lymphocytic Leukemia, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04965493 | |
| Clinical | MedTrace Pharma | As of 10 August 2026, MedTrace Pharma estimated primary completion of a Phase 3 trial in Coronary Artery Disease, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05134012 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 12 March 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06057922 | |
| Clinical | Merz North America | As of 22 May 2026, Merz North America estimated primary completion of a Phase 3 trial in Neuromuscular Agents, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07122193 | |
| Clinical | Mirum Pharmaceuticals | As of 11 August 2026, Mirum Pharmaceuticals estimated primary completion of a Phase 3 trial in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06553768 | |
| Clinical | Novadip Biosciences | As of 1 April 2026, Novadip Biosciences estimated primary completion of a Phase 3 trial in Congenital Pseudarthrosis of Tibia, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07112443 | |
| Clinical | Novaliq | As of 28 July 2026, Novaliq estimated primary completion of a Phase 2 trial in Non-infectious Anterior Uveitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07285070 | |
| Clinical | Novartis Pharmaceuticals | As of 3 July 2025, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Age-Related Macular Degeneration, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05230537 | |
| Clinical | Novo Nordisk | As of 31 July 2026, Novo Nordisk estimated primary completion of a Phase 3 trial in Heart Failure, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06200207 | |
| Clinical | Organon and | As of 17 April 2026, Organon and estimated primary completion of a Phase 3 trial in Plaque Psoriasis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05172726 | |
| Clinical | PersonGen BioTherapeutics (Suzhou) Co. | As of 6 July 2026, PersonGen BioTherapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07188610 | |
| Clinical | Pharming Technologies B.V. | As of 12 February 2026, Pharming Technologies B.V. estimated primary completion of a Phase 2 trial in Common Variable Immunodeficiency (CVID), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06897358 | |
| Clinical | Phathom Pharmaceuticals | As of 29 June 2026, Phathom Pharmaceuticals estimated primary completion of a Phase 2 trial in Eosinophilic Esophagitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06851559 | |
| Clinical | Philogen S.p.A. | As of 10 October 2023, Philogen S.p.A. estimated primary completion of a Phase 2 trial in glioblastoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04443010 | |
| Clinical | Prana Therapies | As of 6 August 2026, Prana Therapies estimated primary completion of a Phase 2 trial in Mild to Moderate Asthma, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07245368 | |
| Clinical | Privo Technologies | As of 23 April 2026, Privo Technologies estimated primary completion of a Phase 3 trial in Oral Squamous Cell Carcinoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05893888 | |
| Clinical | Qilu Pharmaceutical Co. | As of 1 December 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07256782 | |
| Clinical | RemeGen Co. | As of 17 February 2025, RemeGen Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06642545 | |
| Clinical | Research Institute of Geroprotective Technologies | As of 6 May 2026, Research Institute of Geroprotective Technologies estimated primary completion of a Phase 2 trial in Coronary Artery Disease, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07397351 | |
| Clinical | Retension Pharmaceuticals. | As of 29 June 2026, Retension Pharmaceuticals. estimated primary completion of a Phase 2 trial in Uncontrolled Hypertension, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07142356 | |
| Clinical | Senseye | As of 29 April 2026, Senseye estimated primary completion of a Phase 3 trial in PTSD - Post Traumatic Stress Disorder, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07280065 | |
| Clinical | Sernova Biotherapeutics | As of 25 February 2026, Sernova Biotherapeutics estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT03513939 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 1 December 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07229729 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 23 December 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced or Metastatic Non-small Cell Lung Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06512051 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 3 January 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced or Metastatic Esophageal Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06474468 | |
| Clinical | Shanghai Huilun Pharmaceutical Co. | As of 16 July 2026, Shanghai Huilun Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Postoperative Pain, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07709598 | |
| Clinical | Shanghai Huilun Pharmaceutical Co. | As of 13 July 2026, Shanghai Huilun Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Postoperative Pain, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07699601 | |
| Clinical | Shanghai Shengdi Pharmaceutical Co. | As of 24 July 2026, Shanghai Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07231211 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06316531 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 7 May 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Recurrent Glioblastoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06598787 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 6 August 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06423885 | |
| Clinical | Sol-Gel Technologies | As of 11 August 2026, Sol-Gel Technologies estimated primary completion of a Phase 3 trial in Gorlin Syndrome, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06050122 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 6 June 2025, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Recurrent or Metastatic Cervical Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06859775 | |
| Clinical | Suzhou Teligene | As of 28 April 2026, Suzhou Teligene estimated primary completion of a Phase 2 trial in Colorectal Cancer Metastatic, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06589830 | |
| Clinical | Triveni Bio | As of 27 April 2026, Triveni Bio estimated primary completion of a Phase 2 trial in Atopic Dermatitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07167758 | |
| Clinical | USWM CT | As of 11 August 2026, USWM CT estimated primary completion of a Phase 2 trial in Synovial Sarcoma, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05642455 | |
| Clinical | Vanda Pharmaceuticals | As of 27 February 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in hypertension, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07090161 | |
| Clinical | Vyriad | As of 8 July 2026, Vyriad estimated primary completion of a Phase 2 trial in melanoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04291105 | |
| Clinical | Xenon Pharmaceuticals | As of 14 May 2026, Xenon Pharmaceuticals estimated primary completion of a Phase 3 trial in Focal Onset Seizures, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05716100 | |
| Clinical | Zhejiang Sunshine Mandi Pharmaceutical Co. | As of 9 July 2025, Zhejiang Sunshine Mandi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Acne Vulgaris, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06403501 | |
| Clinical | argenx | As of 12 January 2026, argenx estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04812925 | |
| Clinical | PEACHES BIOTECH | As of 10 June 2026, PEACHES BIOTECH estimated primary completion of a Phase 2 trial in sARS-CoV-2, on 2 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06684379 | |
| Clinical | Takeda | As of 8 July 2026, Takeda estimated primary completion of a Phase 3 trial in Narcolepsy Type 1 (NT1), on 2 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07363720 | |
| Clinical | Eddingpharm (Zhuhai) Co. | As of 20 May 2026, Eddingpharm (Zhuhai) Co. estimated primary completion of a Phase 2 trial in Homozygous Familial Hypercholesterolemia (HoFH), on 4 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07489209 |
Week of 5 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | ModernaTX | As of 6 May 2026, ModernaTX estimated primary completion of a Phase 2 trial in Epstein-Barr Virus Infection, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05164094 | |
| Clinical | Swedish Orphan Biovitrum | As of 30 April 2026, Swedish Orphan Biovitrum estimated primary completion of a Phase 3 trial in Primary Myelofibrosis, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03165734 | |
| Clinical | Bristol-Myers Squibb | As of 24 March 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis, on 6 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06003426 | |
| Clinical | Regeneron Pharmaceuticals | As of 29 May 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 7 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02612454 | |
| Clinical | Hoffmann-La Roche | As of 10 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 8 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05805501 | |
| Clinical | Incyte | As of 8 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06958211 | |
| Clinical | Incyte | As of 28 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06959225 | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 23 June 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Plaque Psoriasis, on 10 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07357831 | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 25 September 2025, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 10 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07193459 | |
| Clinical | Biocodex | As of 18 November 2025, Biocodex estimated primary completion of a Phase 3 trial in IBS (Irritable Bowel Syndrome), on 11 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07168434 |
Week of 12 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bristol-Myers Squibb | As of 5 September 2025, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05372354 | |
| Clinical | Janssen Research & Development | As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Metastatic Castrate-sensitive Prostate Cancer, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05884398 | |
| Clinical | Regeneron Pharmaceuticals | As of 30 April 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05133531 | |
| Clinical | Aspa Therapeutics | As of 17 April 2026, Aspa Therapeutics estimated primary completion of a Phase 2 trial in Canavan Disease, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04998396 | |
| Clinical | Daewoong Pharmaceutical Co. | As of 16 July 2026, Daewoong Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05389215 | |
| Clinical | GlaxoSmithKline | As of 12 November 2025, GlaxoSmithKline estimated primary completion of a Phase 2 trial in melanoma, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06521567 | |
| Clinical | Shanghai JMT-Bio | As of 24 March 2025, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06846437 | |
| Clinical | GlaxoSmithKline | As of 28 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07596173 | |
| Clinical | Inozyme Pharma | As of 10 August 2026, Inozyme Pharma estimated primary completion of a Phase 3 trial in Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07473973 | |
| Clinical | Sanofi | As of 20 May 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06834347 | |
| Clinical | AstraZeneca | As of 21 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in RSV Respiratory Syncytial Virus, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07717840 | |
| Clinical | Birch BioMed | As of 4 May 2026, Birch BioMed estimated primary completion of a Phase 3 trial in Burn Scar, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06807021 | |
| Clinical | CanariaBio | As of 1 April 2026, CanariaBio estimated primary completion of a Phase 2 trial in Ovarian Neoplasm Epithelial, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05605535 | |
| Clinical | Eccogene | As of 25 June 2026, Eccogene estimated primary completion of a Phase 2 trial in Adult Obesity, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07505303 | |
| Clinical | Novartis Pharmaceuticals | As of 1 May 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration Resistant Prostate Cancer (mCRPC), on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06894511 | |
| Clinical | Solid Biosciences | As of 10 August 2026, Solid Biosciences estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03368742 | |
| Clinical | Suzhou Alphamab Co. | As of 17 September 2025, Suzhou Alphamab Co. estimated primary completion of a Phase 3 trial in Hemophilia A Without Inhibitor, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06569108 | |
| Clinical | Hoffmann-La Roche | As of 6 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Non-Hodgkins Lymphoma, on 16 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03533283 | |
| Clinical | Kunming Pharmaceuticals | As of 12 December 2025, Kunming Pharmaceuticals estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 18 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07279493 |
Week of 19 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bristol-Myers Squibb | As of 3 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05617677 | |
| Clinical | Bristol-Myers Squibb | As of 2 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05620407 | |
| Clinical | Incyte | As of 14 April 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06516965 | |
| Clinical | Incyte | As of 28 May 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06516952 | |
| Clinical | Pfizer | As of 4 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Atopic Dermatitis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05995964 | |
| Clinical | Biogen | As of 31 July 2026, Biogen estimated primary completion of a Phase 3 trial in Subacute Cutaneous Lupus Erythematosus, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05531565 | |
| Clinical | Bioray Laboratories | As of 21 July 2026, Bioray Laboratories estimated primary completion of a Phase 2 trial in beta-Thalassemia, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05577312 | |
| Clinical | Daiichi Sankyo | As of 17 July 2026, Daiichi Sankyo estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05875168 | |
| Clinical | LEO Pharma | As of 7 July 2026, LEO Pharma estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06311682 | |
| Clinical | Nanjing Leads Biolabs Co. | As of 4 December 2025, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06049290 | |
| Clinical | Otsuka Pharmaceutical Development & Commercialization | As of 31 July 2026, Otsuka Pharmaceutical Development & Commercialization estimated primary completion of a Phase 3 trial in schizophrenia, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06894212 | |
| Clinical | Amgen | As of 8 January 2026, Amgen estimated primary completion of a Phase 3 trial in Sjögren's Syndrome (SS), on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06245408 | |
| Clinical | Hoffmann-La Roche | As of 23 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Progressive Multiple Sclerosis (PMS), on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03523858 | |
| Clinical | Shanghai Henlius Biotech | As of 20 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in SCLC, Extensive Stage, on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06812260 | |
| Clinical | AstraZeneca | As of 2 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 23 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06008093 |
Week of 26 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | CSL Behring | As of 23 April 2026, CSL Behring estimated primary completion of a Phase 3 trial in Congenital Hemophilia A, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06738485 | |
| Clinical | Galderma R&D | As of 12 November 2025, Galderma R&D estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04204616 | |
| Clinical | Novartis Pharmaceuticals | As of 13 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Coronary Artery Disease, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05360446 | |
| Clinical | AstraZeneca | As of 2 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 27 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05775159 | |
| Clinical | Akeso | As of 12 March 2025, Akeso estimated primary completion of a Phase 3 trial in NSCLC (Non-small Cell Lung Cancer), on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06617416 | |
| Clinical | Boehringer Ingelheim | As of 14 May 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Macular Degeneration, Age-related, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06722157 | |
| Clinical | Hoffmann-La Roche | As of 11 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy (SMA), on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05115110 | |
| Clinical | Merck Sharp & Dohme | As of 15 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05239728 | |
| Clinical | Merck Sharp & Dohme | As of 6 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04736706 | |
| Clinical | Novartis Pharmaceuticals | As of 15 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP), on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05653349 | |
| Clinical | Abbisko Therapeutics Co | As of 12 August 2024, Abbisko Therapeutics Co estimated primary completion of a Phase 2 trial in cGvHD, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06186804 | |
| Clinical | Antelope Surgical Solutions | As of 9 July 2026, Antelope Surgical Solutions estimated primary completion of a Phase 2 trial in Prostate Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06906471 | |
| Clinical | Beijing Continent Pharmaceutical Co | As of 31 March 2026, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in Chronic Hepatitis B With Hepatic Fibrosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07343778 | |
| Clinical | Biotheus | As of 11 March 2025, Biotheus estimated primary completion of a Phase 2 trial in tNBC, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05918133 | |
| Clinical | CSPC Ouyi Pharmaceutical Co. | As of 6 April 2026, CSPC Ouyi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07026968 | |
| Clinical | Genzyme, a Sanofi | As of 10 July 2026, Genzyme, a Sanofi estimated primary completion of a Phase 2 trial in Gaucher Disease Type 1, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02843035 | |
| Clinical | Innervate Radiopharmaceuticals | As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Parkinson Disease (PD), on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07176286 | |
| Clinical | Innervate Radiopharmaceuticals | As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Heart Failure, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06965621 | |
| Clinical | Kind Pharmaceuticals | As of 27 March 2026, Kind Pharmaceuticals estimated primary completion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07494409 | |
| Clinical | Laekna | As of 2 April 2026, Laekna estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04851613 | |
| Clinical | Natureceuticals Sdn Bhd | As of 25 June 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07669467 | |
| Clinical | Nouscom SRL | As of 13 February 2026, Nouscom SRL estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04041310 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 2 March 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Unresectable or Metastatic Breast Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06679036 | |
| Clinical | Shanghai Henlius Biotech | As of 17 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Solid Tumor Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06848699 | |
| Clinical | Tyligand Pharmaceuticals (Suzhou) | As of 24 April 2026, Tyligand Pharmaceuticals (Suzhou) estimated primary completion of a Phase 2 trial in Malignant Neoplasm, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06385925 | |
| Clinical | Vertex Pharmaceuticals Incorporated | As of 21 July 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Cystic Fibrosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05444257 | |
| Clinical | Vidya Therapeutics | As of 21 July 2026, Vidya Therapeutics estimated primary completion of a Phase 2 trial in Multiple Sclerosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07085507 | |
| Clinical | Adagene | As of 7 January 2026, Adagene estimated primary completion of a Phase 2 trial in Advanced/Metastatic Solid Tumors, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05405595 | |
| Clinical | Amgen | As of 28 May 2026, Amgen estimated primary completion of a Phase 2 trial in MTAP-deleted NSCLC, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06593522 | |
| Clinical | Animuscure | As of 3 August 2026, Animuscure estimated primary completion of a Phase 2 trial in Sarcopenia in Elderly, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07072195 | |
| Clinical | Annexon | As of 4 May 2026, Annexon estimated primary completion of a Phase 3 trial in Geographic Atrophy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06510816 | |
| Clinical | AskBio | As of 3 December 2025, AskBio estimated primary completion of a Phase 2 trial in Congestive Heart Failure, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05598333 | |
| Clinical | AstraZeneca | As of 27 March 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06635447 | |
| Clinical | Avistone Biotechnology Co. | As of 21 May 2025, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06574347 | |
| Clinical | Changzhou Qianhong Bio-pharma Co. | As of 9 February 2026, Changzhou Qianhong Bio-pharma Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07396337 | |
| Clinical | Genentech | As of 25 February 2026, Genentech estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06524375 | |
| Clinical | Hoffmann-La Roche | As of 11 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05852691 | |
| Clinical | Hoffmann-La Roche | As of 5 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03178552 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 13 December 2024, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06083207 | |
| Clinical | Janssen Research & Development | As of 6 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Atrial Fibrillation, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05757869 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 1 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04842617 | |
| Clinical | Longboard Pharmaceuticals | As of 17 July 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Developmental and Epileptic Encephalopathy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06719141 | |
| Clinical | MaaT Pharma | As of 27 December 2024, MaaT Pharma estimated primary completion of a Phase 2 trial in Transplant Complication, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05762211 | |
| Clinical | Myosin Therapeutics | As of 14 April 2026, Myosin Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma (GBM), on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07185880 | |
| Clinical | NEXTGEN Bioscience | As of 13 April 2026, NEXTGEN Bioscience estimated primary completion of a Phase 2 trial in Alopecia Areata, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06104839 | |
| Clinical | Natureceuticals Sdn Bhd | As of 25 June 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07669454 | |
| Clinical | Neurimmune | As of 19 December 2025, Neurimmune estimated primary completion of a Phase 2 trial in Amyloid Transthyretin Cardiomyopathy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07213583 | |
| Clinical | Rhythm Pharmaceuticals | As of 12 February 2026, Rhythm Pharmaceuticals estimated primary completion of a Phase 2 trial in Prader-Willi Syndrome, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06772597 | |
| Clinical | Salubris Biotherapeutics | As of 22 May 2026, Salubris Biotherapeutics estimated primary completion of a Phase 2 trial in Heart Failure With Reduced Ejection Fraction, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06369298 | |
| Clinical | Sarepta Therapeutics | As of 27 February 2026, Sarepta Therapeutics estimated primary completion of a Phase 3 trial in Muscular Dystrophy, Duchenne, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03992430 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 25 November 2024, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06222879 | |
| Clinical | Shanghai Henlius Biotech | As of 18 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Esophageal Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06769113 | |
| Clinical | Shanghai Henlius Biotech | As of 10 March 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Carcinoma, Hepatocellular, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06742892 | |
| Clinical | Spyre Therapeutics | As of 5 June 2026, Spyre Therapeutics estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07148414 | |
| Clinical | TG Therapeutics | As of 17 July 2026, TG Therapeutics estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07211633 | |
| Clinical | Takeda | As of 30 March 2026, Takeda estimated primary completion of a Phase 3 trial in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04129502 | |
| Clinical | Takeda | As of 25 February 2026, Takeda estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02716116 | |
| Clinical | Teva Branded Pharmaceutical Products R&D | As of 24 July 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06052267 | |
| Clinical | Topadur Pharma | As of 15 June 2026, Topadur Pharma estimated primary completion of a Phase 2 trial in Digital Ulcers in Systemic Sclerosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06954597 | |
| Clinical | Viatris Innovation | As of 28 July 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05672576 | |
| Clinical | Viatris Innovation | As of 28 July 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05648500 | |
| Clinical | AbbVie | As of 9 February 2026, AbbVie estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia (CLL), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04895436 | |
| Clinical | AbbVie | As of 28 October 2025, AbbVie estimated primary completion of a Phase 2 trial in High Grade Ovarian Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05456685 | |
| Clinical | AbbVie | As of 17 June 2026, AbbVie estimated primary completion of a Phase 2 trial in Generalized Anxiety Disorder (GAD), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06846320 | |
| Clinical | AbbVie | As of 14 August 2025, AbbVie estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05822752 | |
| Clinical | Acesion Pharma | As of 12 June 2026, Acesion Pharma estimated primary completion of a Phase 2 trial in Atrial Fibrillation (AF), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07267949 | |
| Clinical | Admetsys | As of 30 July 2024, Admetsys estimated primary completion of a Phase 2 trial in hyperglycemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT01291719 | |
| Clinical | Akeso | As of 24 June 2024, Akeso estimated primary completion of a Phase 3 trial in Gastric and Gastroesophageal Junction Adenocarcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06341335 | |
| Clinical | Alkermes | As of 24 June 2026, Alkermes estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06843590 | |
| Clinical | Anbogen Therapeutics | As of 24 June 2024, Anbogen Therapeutics estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05532696 | |
| Clinical | Apogee Therapeutics | As of 22 July 2026, Apogee Therapeutics estimated primary completion of a Phase 2 trial in Atopic Dermatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06395948 | |
| Clinical | Aptose Biosciences | As of 26 August 2025, Aptose Biosciences estimated primary completion of a Phase 2 trial in Leukemia, Myeloid, Acute, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT03850574 | |
| Clinical | Arthrosi Therapeutics | As of 15 May 2026, Arthrosi Therapeutics estimated primary completion of a Phase 2 trial in gout, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07116746 | |
| Clinical | Atossa Therapeutics | As of 8 July 2026, Atossa Therapeutics estimated primary completion of a Phase 2 trial in Breast Neoplasms, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05607004 | |
| Clinical | Avistone Biotechnology Co. | As of 20 March 2026, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07336732 | |
| Clinical | BeOne Medicines | As of 6 August 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in B-cell Malignancy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05006716 | |
| Clinical | BeOne Medicines | As of 9 July 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06637501 | |
| Clinical | BeOne Medicines | As of 7 August 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04973605 | |
| Clinical | Beckley Psytech | As of 6 July 2026, Beckley Psytech estimated primary completion of a Phase 2 trial in Treatment Resistant Depression, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05660642 | |
| Clinical | BeiGene | As of 10 July 2026, BeiGene estimated primary completion of a Phase 2 trial in MSI-H/dMMR Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT03736889 | |
| Clinical | BioNTech SE | As of 15 July 2026, BioNTech SE estimated primary completion of a Phase 2 trial in Colorectal Cancer Stage II, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04486378 | |
| Clinical | Bristol-Myers Squibb | As of 27 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06951698 | |
| Clinical | CG Oncology | As of 1 July 2026, CG Oncology estimated primary completion of a Phase 3 trial in Non Muscle Invasive Bladder Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06111235 | |
| Clinical | Calluna Pharma AS | As of 27 April 2026, Calluna Pharma AS estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06736990 | |
| Clinical | Camurus | As of 28 July 2026, Camurus estimated primary completion of a Phase 3 trial in Gastro-enteropancreatic Neuroendocrine Tumor, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05050942 | |
| Clinical | Cardiff Oncology | As of 16 June 2026, Cardiff Oncology estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06106308 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. | As of 19 September 2025, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Pancreatic Neoplasms, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06767813 | |
| Clinical | Colgate Palmolive | As of 27 May 2026, Colgate Palmolive estimated primary completion of a Phase 3 trial in Plaque, Dental, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07605338 | |
| Clinical | Corbus Pharmaceuticals | As of 3 June 2025, Corbus Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumor, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06603844 | |
| Clinical | DBV Technologies | As of 22 July 2026, DBV Technologies estimated primary completion of a Phase 3 trial in allergy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07003919 | |
| Clinical | Eli Lilly and | As of 1 May 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Acute Pain, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07511816 | |
| Clinical | Eli Lilly and | As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in obesity, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06662383 | |
| Clinical | Eli Lilly and | As of 12 May 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06914895 | |
| Clinical | Eli Lilly and | As of 17 February 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06962280 | |
| Clinical | Eli Lilly and | As of 29 September 2025, Eli Lilly and estimated primary completion of a Phase 3 trial in oSA, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06649045 | |
| Clinical | Eli Lilly and | As of 13 July 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07215312 | |
| Clinical | Epygenix | As of 2 July 2026, Epygenix estimated primary completion of a Phase 3 trial in Lennox Gastaut Syndrome, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05066217 | |
| Clinical | Erasca | As of 22 June 2026, Erasca estimated primary completion of a Phase 2 trial in Advanced or Metastatic Solid Tumors, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04866134 | |
| Clinical | Ferrer Internacional | As of 15 October 2025, Ferrer Internacional estimated primary completion of a Phase 2 trial in Progressive Supranuclear Palsy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06355531 | |
| Clinical | Forge Biologics | As of 2 June 2026, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04693598 | |
| Clinical | Forge Biologics | As of 20 November 2025, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05739643 | |
| Clinical | Immunic | As of 23 February 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05134441 | |
| Clinical | Immunic | As of 23 February 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, Relapsing-Remitting, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05201638 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 5 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in HER2-expressing Advanced Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06015048 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 12 March 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Local Analgesia Via Nerve Block, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06529432 | |
| Clinical | KeyBioscience | As of 19 February 2025, KeyBioscience estimated primary completion of a Phase 2 trial in Osteoarthritis in the Knee, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06833749 | |
| Clinical | Kiora Pharmaceuticals | As of 16 June 2026, Kiora Pharmaceuticals estimated primary completion of a Phase 2 trial in Macular Edema, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06825702 | |
| Clinical | LG Chem | As of 3 July 2025, LG Chem estimated primary completion of a Phase 3 trial in diphtheria, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06947499 | |
| Clinical | Lynk Pharmaceuticals Co. | As of 20 November 2025, Lynk Pharmaceuticals Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07237568 | |
| Clinical | ML Bio Solutions | As of 21 July 2026, ML Bio Solutions estimated primary completion of a Phase 2 trial in lGMD2I, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04800874 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 26 November 2025, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in nSCLC, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06107686 | |
| Clinical | Medicure | As of 16 October 2025, Medicure estimated primary completion of a Phase 3 trial in Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04706013 | |
| Clinical | NeuShen Therapeutics | As of 13 April 2026, NeuShen Therapeutics estimated primary completion of a Phase 2 trial in schizophrenia(Acute), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07521683 | |
| Clinical | NewAmsterdam Pharma | As of 4 June 2024, NewAmsterdam Pharma estimated primary completion of a Phase 3 trial in Atherosclerotic Cardiovascular Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05202509 | |
| Clinical | NewAmsterdam Pharma | As of 9 April 2026, NewAmsterdam Pharma estimated primary completion of a Phase 2 trial in dyslipidemias, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06496243 | |
| Clinical | Nuance Hearing | As of 15 December 2025, Nuance Hearing estimated primary completion of a Phase 3 trial in Hearing Loss Mixed, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07282028 | |
| Clinical | Pacira Pharmaceuticals | As of 7 August 2026, Pacira Pharmaceuticals estimated primary completion of a Phase 2 trial in Osteoarthritis (OA) of the Knee, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06884865 | |
| Clinical | Pharmazz | As of 31 December 2025, Pharmazz estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05514340 | |
| Clinical | Pharming Technologies B.V. | As of 13 February 2026, Pharming Technologies B.V. estimated primary completion of a Phase 2 trial in Primary Immunodeficiency Disorders (PIDs), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06549114 | |
| Clinical | Reunion Neuroscience | As of 6 August 2026, Reunion Neuroscience estimated primary completion of a Phase 2 trial in Adjustment Disorder, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07002034 | |
| Clinical | SK Life Science | As of 3 April 2026, SK Life Science estimated primary completion of a Phase 3 trial in Partial Epilepsy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05067634 | |
| Clinical | Sandoz | As of 29 May 2026, Sandoz estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06847724 | |
| Clinical | Scholar Rock | As of 25 May 2025, Scholar Rock estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05626855 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 30 April 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Primary Aldosteronism, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07470983 | |
| Clinical | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. | As of 27 March 2026, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 trial in Seasonal Allergic Rhinitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07398859 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Nasopharyngeal Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06118333 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 21 January 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06668961 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06448312 | |
| Clinical | Sinovac Biotech Co. | As of 10 August 2026, Sinovac Biotech Co. estimated primary completion of a Phase 3 trial in Epidemic Meningitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07505888 | |
| Clinical | Stemline Therapeutics | As of 7 May 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05596409 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 9 January 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Malignant Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06737731 | |
| Clinical | Suzhou Zelgen Biopharmaceuticals Co. | As of 5 January 2026, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05584800 | |
| Clinical | Tyra Biosciences | As of 12 January 2026, Tyra Biosciences estimated primary completion of a Phase 2 trial in Locally Advanced Urothelial Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05544552 | |
| Clinical | Vir Biotechnology | As of 16 January 2026, Vir Biotechnology estimated primary completion of a Phase 2 trial in Viral Hepatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07142811 | |
| Clinical | Waterstone Pharmaceutical (Wuhan) Co. | As of 26 November 2025, Waterstone Pharmaceutical (Wuhan) Co. estimated primary completion of a Phase 3 trial in hyperkalemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07251309 | |
| Clinical | Wooshin Labottach Co. | As of 26 January 2026, Wooshin Labottach Co. estimated primary completion of a Phase 3 trial in Nail Psoriasis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07029516 | |
| Clinical | Xentria | As of 30 July 2026, Xentria estimated primary completion of a Phase 2 trial in Pulmonary Sarcoidosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06169397 | |
| Clinical | Zura Bio | As of 30 June 2026, Zura Bio estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa (HS), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06993610 | |
| Clinical | argenx | As of 25 September 2025, argenx estimated primary completion of a Phase 2 trial in dermatomyositis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06284954 | |
| Clinical | medac | As of 27 August 2025, medac estimated primary completion of a Phase 3 trial in Moderate to Severe Atopic Dermatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06239311 |
Week of 2 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AstraZeneca | As of 29 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Cutaneous Lupus Erythematosus, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06015737 | |
| Clinical | Bristol-Myers Squibb | As of 20 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06951711 | |
| Clinical | GlaxoSmithKline | As of 26 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Rectal, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05723562 | |
| Clinical | Keymed Biosciences Co. | As of 9 April 2026, Keymed Biosciences Co. estimated primary completion of a Phase 2 trial in Chronic Spontaneous Urticaria (CSU), on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07166211 | |
| Clinical | Regeneron Pharmaceuticals | As of 10 February 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in melanoma, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06190951 | |
| Clinical | Novartis Pharmaceuticals | As of 20 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, on 3 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05677451 | |
| Clinical | CMG Pharmaceutical Co. | As of 15 January 2026, CMG Pharmaceutical Co. estimated primary completion of a Phase 3 trial in dyslipidemia, on 4 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06772168 | |
| Clinical | Genzyme, a Sanofi | As of 17 December 2025, Genzyme, a Sanofi estimated primary completion of a Phase 3 trial in hemophilia, on 5 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03754790 | |
| Clinical | Incyte | As of 25 June 2026, Incyte estimated primary completion of a Phase 2 trial in B-Cell Malignancies, on 5 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04509700 | |
| Clinical | Merck Sharp & Dohme | As of 19 February 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hodgkin Lymphoma, on 6 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03407144 | |
| Clinical | Sanofi | As of 2 June 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 6 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06834360 |
Week of 9 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bio-Thera Solutions | As of 13 August 2025, Bio-Thera Solutions estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 9 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06376136 | |
| Clinical | GlaxoSmithKline | As of 15 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Lung Cancer, Non-Small Cell, on 9 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05565378 | |
| Clinical | Gan & Lee Pharmaceuticals. | As of 25 November 2025, Gan & Lee Pharmaceuticals. estimated primary completion of a Phase 3 trial in diabetes, on 10 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07165223 | |
| Clinical | HELP Therapeutics Co. | As of 10 February 2026, HELP Therapeutics Co. estimated primary completion of a Phase 2 trial in Heart Failure, on 10 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06340048 |
What this does not cover
The calendar reads government registers and nothing else. It has no view of anything a company has not filed, and no free source publishes pending FDA goal dates, so approval decision dates are absent by construction rather than by omission. An empty week is not evidence that nothing is scheduled that week. Read a gap as a gap in the registers.
Complete response letters are never published here. Neither are live offerings. Both exclusions are deliberate and permanent. The methodology page sets out every source, every gate and the current drop rate.
How it is compiled
Rows are written automatically from primary documents once a day. Nobody reviews each row before it appears. Every sentence is composed from structured fields taken out of the filing, never from the wording of the source, and each one carries the date on which the claim was made so it stays true after a date slips.
Not investment advice
Nothing here is a recommendation to buy or sell anything, and none of it is tailored to any reader. This page is identical for every visitor. It reports what public registers say, and public registers are wrong often enough that you should check the linked document before you act on a row.
Corrections and takedown
Write to calendar@julienwillard.com with the reference identifier of the row. Corrections and takedown requests are answered within two business days. No call is needed and none will be asked for.
When a row changes
A row whose date moves keeps its identity and gains a note saying where it moved from, so a calendar subscription updates the event in place instead of adding a second one. A withdrawn row stays visible for 30 days, struck through, and is listed on the changes page. Nothing disappears without a record.
Citing this page
Willard, J. Biotech catalyst calendar. julienwillard.com/calendar, as of 12 August 2026, 01:32 UTC. Licensed CC BY 4.0.